Compare UTHR & RBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | RBA |
|---|---|---|
| Founded | 1996 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 20.0B |
| IPO Year | 1999 | 1998 |
| Metric | UTHR | RBA |
|---|---|---|
| Price | $476.81 | $100.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $495.08 | $122.00 |
| AVG Volume (30 Days) | 424.3K | ★ 967.4K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 1.24% |
| EPS Growth | ★ 16.08 | 14.05 |
| EPS | ★ 26.38 | 2.10 |
| Revenue | $3,128,400,000.00 | ★ $4,528,900,000.00 |
| Revenue This Year | $13.64 | $6.20 |
| Revenue Next Year | $5.78 | $4.20 |
| P/E Ratio | ★ $18.55 | $47.46 |
| Revenue Growth | ★ 13.50 | 8.26 |
| 52 Week Low | $266.98 | $86.68 |
| 52 Week High | $492.62 | $119.58 |
| Indicator | UTHR | RBA |
|---|---|---|
| Relative Strength Index (RSI) | 56.84 | 53.16 |
| Support Level | $470.13 | $97.51 |
| Resistance Level | $492.62 | $99.09 |
| Average True Range (ATR) | 10.91 | 1.58 |
| MACD | -1.22 | 0.50 |
| Stochastic Oscillator | 41.31 | 91.83 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
RB Global has evolved into a leading global marketplace that connects buyers and sellers of commercial assets and vehicles. It is the result of the 2023 combination of Ritchie Bros. and IAA. Ritchie Bros.' roots were as an auctioneer facilitating transactions of commercial, construction, and transportation equipment (excavators, bulldozers, forklifts, and commercial trucks and trailers). However, it has evolved into an omnichannel marketplace. IAA has similar roots, though primarily focused on the salvage auction segment for consumer automobiles. The group provides ancillary services including title processing, transportation/towing, financing, data and appraisal, and so on. Its activities are international, though skewing approximately two-thirds to North America.